By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
Panel consensus is that New York Life's reduction of NTSK position is a de-risking move, not a fundamental capitulation. While the company has a strong cash runway and positive FCF, the high burn rate and lack of GAAP profitability are significant concerns.
Risk: High burn rate and lack of GAAP profitability, which could lead to dilution and further compress the valuation.
Opportunity: Potential re-acceleration in growth if the company executes on AI workload security and improves operating leverage.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
New York Life sold 338,958 Netskope shares in the first quarter; the estimated transaction value was $4.21 million based on quarterly average prices.
Meanwhile, the quarter-end position value decreased by $15.31 million, reflecting both trading activity and stock price movement.
The fund now holds 1,035,245 Netskope shares, valued at $8.79 million as of March 31, 2026.
On May 7, 2026, New York Life Insurance Co disclosed in an SEC filing that it sold 338,958 shares of Netskope (NASDAQ:NTSK), an estimated $4.21 million trade based on quarterly average pricing.
According to a Securities and Exchange Commission (SEC) filing dated May 7, 2026, New York Life Insurance Co sold 338,958 shares of Netskope during the first quarter of 2026. The estimated transaction value is $4.21 million, based on the average unadjusted closing price for the quarter. The fund’s quarter-end position in Netskope declined in value by $15.31 million, a figure that includes both share sales and price movement.
NYSEMKT:MMCA: $24.83 million (5.1% of AUM)
As of May 6, 2026, Netskope shares were priced at $11. Shares have tumbled about 52% since the firm’s September IPO.
| Metric | Value | |---|---| | Price | $11 | | Market Capitalization | $4.4 billion | | Revenue (TTM) | $709.00 million | | Net Income (TTM) | ($679.39 million) |
Netskope, Inc. is a technology company specializing in cloud security, with a focus on providing comprehensive data protection and secure access for modern enterprise IT environments. The company leverages its unified platform to address the evolving security needs of organizations adopting SaaS, web, and AI workloads. With a scalable subscription model and a customer base concentrated among large enterprises, Netskope positions itself as a leader in the cloud security sector.
Netskope shares have been on a rough ride since the firm’s September IPO, falling about 50%. Fundamentally, however, Netskope’s latest quarter was actually solid. Fourth-quarter revenue climbed 32% year over year to $196.3 million, while ARR rose 31% to $811 million. The company also generated positive free cash flow for the first full fiscal year in its history and ended January with roughly $1.2 billion in cash, cash equivalents, and marketable securities.
The problem was the outlook. Netskope forecasts fiscal 2027 revenue between $870 million and $876 million, implying growth of roughly 23%, a notable deceleration from the 32% growth it posted in fiscal 2026, and investors, of course, took note.
Still, New York Life maintains a non-negligible stake in the firm, signaling that the sale doesn’t necessarily reflect a complete loss of faith in Netskope’s business, but instead a risk-reduction move ahead of what could be a complicated growth story.
Before you buy stock in Netskope, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Netskope wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $476,034! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,274,109!
Now, it’s worth noting Stock Advisor’s total average return is 975% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 7, 2026. *
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Vanguard S&P 500 ETF. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Netskope's shift toward positive free cash flow provides a defensive floor that outweighs the optics of institutional selling as the company matures into a slower, more sustainable growth profile."
New York Life’s trimming of NTSK is a classic institutional de-risking move, not a fundamental capitulation. At a $4.4 billion market cap and 6.2x forward revenue (based on the $709M TTM and projected growth), the valuation is compressing toward a more realistic SaaS multiple as growth decelerates from 32% to 23%. While the 50% post-IPO drawdown is painful, the company’s transition to positive free cash flow is the real story here. With $1.2 billion in liquidity, NTSK has the runway to navigate the 'complicated growth story' without needing dilutive financing. I see this as a bottoming process where the weak hands are finally exiting.
The deceleration to 23% growth in a high-interest rate environment suggests NTSK is losing its 'hyper-growth' premium, which could lead to further multiple contraction regardless of cash flow improvements.
"Netskope's growth deceleration to 23% FY27 guidance amid massive losses and sector competition validates the 52% post-IPO drop, with New York Life's trim signaling broader caution."
Netskope (NTSK) shares are down 52% since September 2025 IPO, trading at $11 with $4.4B market cap on $709M TTM revenue but crushing -$679M net losses (-96% margins), likely from stock-based comp and R&D in cloud security. Q4 FY26 showed 32% revenue growth to $196M and 31% ARR to $811M, plus first positive FCF year and $1.2B cash—impressive. But FY27 guidance of $870-876M (23% growth) triggered the selloff, signaling deceleration in a sector demanding 30%+ for valuation support (currently ~5x forward sales). New York Life's $4M sale trimmed exposure from 5.3% to 1.8% of its $491M AUM—smart de-risking amid competitive pressures from ZS, PANW. Risks: Macro IT spend cuts could worsen churn in large-enterprise focus.
Netskope's $1.2B cash provides multi-year runway, positive FCF inflection proves execution, and AI-driven cloud security tailwinds could easily beat conservative 23% guidance, turning 5x forward sales into a steal versus Zscaler's 15x+.
"NTSK's 50% post-IPO crash has compressed valuation to reasonable levels for a high-growth, FCF-positive security platform, but the deceleration trajectory—not the absolute growth rate—will determine if this is a value trap or a reset."
New York Life's 25% position reduction looks like classic de-risking, not capitulation. The fund still holds 1M+ shares worth $8.79M—they're not fleeing. What's buried: NTSK trades at 6.2x revenue against a 23% growth forecast (down from 32%), which is actually reasonable for a profitable-FCF cloud security play. The real issue is the deceleration narrative. But the article omits that enterprise security spending remains resilient, and 31% ARR growth with $1.2B cash suggests runway for re-acceleration if they execute on AI workload security—a genuine tailwind. New York Life's trim likely reflects valuation normalization post-IPO hype, not fundamental deterioration.
If 32%-to-23% deceleration signals market saturation or customer churn, the stock could fall further; New York Life may know something about Q1 2026 performance we don't yet, making their exit prescient rather than cautious.
"Despite near-term momentum, Netskope’s 2027 guidance signals a meaningful growth slowdown that may justify a lower multiple and continued underperformance unless margin expansion or secular demand surprises materialize."
New York Life’s $4.2m Netskope sale hints at portfolio rebalancing rather than a conviction trade on Netskope. The stock has cratered about 50% since the IPO, yet the latest quarter showed solid momentum: Q4 revenue +32% YoY to $196.3m, ARR up 31% to $811m, and a meaningful cash cushion with positive free cash flow for the first full fiscal year and ~ $1.2b on hand. The caveat is fiscal 2027 guidance of $870–$876m revenue, still ~23% growth, which implies a deceleration from 2026. With a $4.4b market cap and ongoing losses, the stock trades on a long-duration growth story; any AI/security demand surprise or margin improvement could re-rate, but the bar is high.
Devil’s advocate: the sale may reflect liquidity needs or tax harvesting rather than a downgrade of Netskope’s business; a relief rally could occur if results beat and the AI/security cycle remains intact.
"Netskope's massive net losses and reliance on stock-based compensation make their cash runway less impressive than the FCF inflection suggests."
Grok and Claude are glossing over the 'net loss' reality. A 96% net margin deficit isn't just 'R&D investment'; it’s a massive structural burn rate that makes the $1.2B cash runway misleading if they can't achieve GAAP profitability soon. Even with positive FCF, if they rely on stock-based compensation to mask operating losses, the dilution will erode shareholder value. NTSK isn't just a growth story; it's a burn-rate gamble that needs to prove operating leverage, not just ARR growth.
"NTSK's valuation offers no buffer versus peers given deceleration and loss scale."
Gemini spotlights the burn flaw others ignore, but nobody connects it to peers: ZS trades 15x forward sales on 25%+ growth and narrowing losses, while NTSK's 5x on 23% deceleration and 96% net loss margins leaves no margin for error. PANW's ecosystem moat adds competitive pressure—expect 3-4x compression if Q1 misses.
"SBC dilution, not absolute burn, is why NTSK trades at a discount despite better FCF than peers—and New York Life likely sees that gap as unfillable without aggressive share buybacks."
Gemini's burn-rate critique is valid, but conflates two issues: NTSK's -$679M net loss includes $400M+ stock-based comp (non-cash). Actual cash burn is far lower—they achieved positive FCF despite the GAAP loss, which is the operational reality that matters. However, Grok's peer comparison is the real tell: ZS at 15x forward sales on 25% growth versus NTSK at 5x on 23% *should* signal value, but it doesn't—because markets price in ZS's path to profitability while NTSK's SBC dilution remains unresolved. That's the actual structural problem.
"Netskope’s GAAP losses and dilution risk threaten the sustainability of the 'cheap 5x' narrative."
Main risk Grok downplays: the 96% net loss is not a transient issue tied to R&D; even with SBC being non-cash, the cash burn linked to operations remains sizable. If growth decelerates or AI-security demand stalls, Netskope may need more equity or debt to fund ops, pressuring the stock. The 5x forward sales multiple can compress further, not only due to valuation, but due to dilution risk and margin fade.
Panel consensus is that New York Life's reduction of NTSK position is a de-risking move, not a fundamental capitulation. While the company has a strong cash runway and positive FCF, the high burn rate and lack of GAAP profitability are significant concerns.
Potential re-acceleration in growth if the company executes on AI workload security and improves operating leverage.
High burn rate and lack of GAAP profitability, which could lead to dilution and further compress the valuation.